RPRX — Royalty Pharma plc

Summary of Royalty Pharma's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Portfolio Receipts: Grew by 6% to $773 million, exceeding guidance.
• Total Receipts: Increased by 14%, reflecting strong recurring cash flows.
• Return on Invested Capital (ROIC): 14.2% for the last 12 months.
• Return on Invested Equity (ROE): 20.1% for the last 12 months.
• Cash Flow: Adjusted EBITDA less net interest paid was $736 million, with a 95% margin.
• Capital Deployment: $1.1 billion spent on royalty acquisitions in 2026, with $349 million in Q2 alone.
• Share Repurchases: Approximately $100 million in the first half of 2026, reducing share count by 1%.

2. Strategic Updates and Business Highlights

• Royalty Acquisition: Acquired a royalty on AstraZeneca's cliramitug, a potential blockbuster for transthyretin amyloid cardiomyopathy, with a total deal value of up to $425 million.
• Regulatory Approvals: Positive updates from partners, including approvals for Gilead's Trodelvy and GSK's Jideytro.
• Development Pipeline: Expanded from 3 to 19 potential therapies since the IPO, with peak royalty potential increasing over 30-fold.
• Market Position: Royalty Pharma maintains a leading position in the biopharma royalty market, with a focus on innovative therapies and partnerships.

3. Forward Guidance and Outlook

• 2026 Full-Year Guidance: Increased to $3.4 billion to $3.5 billion in portfolio receipts, up from previous guidance of $3.325 billion to $3.45 billion.
• Royalty Receipt Growth: Expected to be around 7% to 10%, revised from 4% to 8%.
• Milestones and Other Receipts: Anticipated to decrease from $128 million in 2025 to approximately $60 million in 2026.

4. Bad News, Challenges, or Points of Concern

• Loss of Exclusivity: Promacta is facing loss of exclusivity, which could impact future revenues.
• Biosimilars: The launch of biosimilar Tysabri in the U.S. may affect sales.
• Regulatory Risks: Potential U.S. policy risks regarding proposed license restrictions could impact future operations in China.
• Market Dynamics: The competitive landscape in the TTR amyloidosis market is evolving, with concerns raised about the implications of recent clinical trial data on existing products.

5. Notable Q&A Insights

• M&A Flexibility: Management expressed confidence in their ability to adapt deal structures in response to increasing pharma-to-biotech M&A activity.
• Development Stage Investments: The company is open to increasing investments in development-stage assets, which typically offer higher IRR expectations.
• China Market Strategy: Royalty Pharma is committed to building a presence in China, viewing it as a significant long-term opportunity despite current geopolitical uncertainties.
• Adverse Selection in R&D Co-Funding: Management emphasized their high standards for funding opportunities, ensuring they target the most promising assets.

Overall, Royalty Pharma reported a strong quarter with solid financial performance and strategic advancements, while also acknowledging certain challenges and risks that could impact future growth.